Insights Into Nasal Pathways for Brain Protein Sampling and Treatment Delivery: Mony de Leon, EdD
The director of the Brain Health Imaging Institute in the department of radiology at Weill Cornell Medicine talked about exploring nasal pathways as an alternative for brain protein sampling and drug delivery. [WATCH TIME: 4 minutes]
WATCH TIME: 4 minutes
We observed that the flow from the brain was reduced in patients with amyloid. In the nose, we saw the same thing, that the outflow was reduced."
Previous studies suggest that a reduction of clearance in cerebrospinal fluid (CSF) may be a pathological feature of Alzheimer disease (AD). Findings from nonhuman mammals and contradictory human neuroimaging data showed that it has remained questionable whether the nasal mucosa is a CSF drainage site among patients. A newly published study in Fluids and Barriers of the CNS used dynamic PET with [1-11C]-Butanol, a highly permeable radiotracer with no appreciable brain binding, to examine whether brain and nasal fluid drainage times were correlated and affected by brain amyloid.1
Led by
de Leon, director of the Brain Health Imaging Institute and professor of neuroscience in the department of radiology at Weill Cornell Medicine, recently sat down with NeurologyLive® in an interview to discuss how nasal pathways can be utilized for noninvasive brain protein sampling. He also talked about the implications of using nasal pathways for drug delivery to the brain, as gathered from the implications of the study. Additionally, de Leon spoke about how the nasal-brain interface may impact the regulation of brain protein outflow and immune system interactions.
REFERENCES
1. Mehta NH, Wang X, Keil SA, et al. [1-11C]-Butanol Positron Emission Tomography reveals an impaired brain to nasal turbinates pathway in aging amyloid positive subjects. Fluids Barriers CNS. 2024;21(1):30. Published 2024 Apr 2. doi:10.1186/s12987-024-00530-y
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
- Current Challenges and New Opportunities Ahead for Women in Neurology
September 15th 2025
- Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
September 15th 2025
- 2025 Women in Neurology Conference: Educating, Mentoring, and Networking
September 15th 2025